Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn’s disease in China

Table 1 Summary of efficacy and safety of biologics for treating moderate to severe Crohn’s disease

	Biological-naïve		Biological-exposed		Serious adverse event (%)
	Response rate (%)	Remission rate (%)	Response rate (%)	Remission rate (%)
Induction phase
IFX	86.12	43.27	30.68	12.28	6.61
ADA	41.26	33.63	35.38	28.29	4.46
UST	44.04	30.67	38.18	17.96	5.28
VDZ	32.67	25.09	30.68	12.28	6.87
PBO	22.00	11.00	20.00	10.00	7.00
Maintenance phase
IFX	62.17	47.34	34.06	17.45	16.14
ADA	87.80	84.51	34.06	17.45	11.27
UST	89.84	84.90	69.90	49.76	13.16
VDZ	61.13	46.81	34.06	17.45	16.72
PBO	39.00	32.00	26.00	16.00	17.00

ADA: Adalimumab; IFX: Infliximab; PBO: Placebo; UST: Ustekinumab; VDZ: Vedolizumab.